PALI logo

Palisade Bio, Inc.

PALI
Healthcare|Biotechnology|US
$1.13
-0.03 (-2.59%)
DCF Value
$2.39
Tangible Book / Share
$0.58
Cash / Share
$0.59
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest May 12, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (1)

Oct 2027
Est. completion
P2Ulcerative Colitis (UC)
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487n=204

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jan 2026
P1
A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease
NCT07428096

Recent Press Releases

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
Oct 28, 2026 · GlobeNewsWire
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Oct 20, 2026 · GlobeNewsWire
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026
Sep 28, 2026 · GlobeNewsWire
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Sep 23, 2026 · GlobeNewsWire
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD
Sep 22, 2026 · GlobeNewsWire
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Sep 21, 2026 · GlobeNewsWire
Palisade Bio to Participate in Upcoming Investor Conferences
Sep 3, 2026 · GlobeNewsWire
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Aug 10, 2026 · Globe News Wire

SEC Filings (88)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 30, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 10, 20268-KMaterial eventDocumentIndex
Aug 10, 202610-QQuarterly reportDocumentIndex
Jul 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
Jun 10, 2026S-8Employee stock planDocumentIndex
May 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 21, 2026EFFECTDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 12, 2026S-3Shelf registrationDocumentIndex
May 12, 20268-KMaterial eventDocumentIndex
May 12, 202610-QQuarterly reportDocumentIndex
Apr 29, 2026ARSAnnual report to holdersDocumentIndex
Apr 29, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 29, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 2, 20268-KMaterial eventDocumentIndex
Mar 20, 202610-KAnnual reportDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 10, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Dec 8, 2025SC 13GPassive 5%+ stakeDocumentIndex
Dec 4, 20258-KMaterial eventDocumentIndex
Nov 12, 2025S-8Employee stock planDocumentIndex
Nov 10, 202510-QQuarterly reportDocumentIndex
Nov 3, 2025DEFA14AProxy / shareholder voteDocumentIndex
Oct 28, 2025DEF 14AProxy / shareholder voteDocumentIndex
Oct 22, 20258-KMaterial eventDocumentIndex
Oct 20, 20258-KMaterial eventDocumentIndex
Oct 16, 20258-KMaterial eventDocumentIndex